CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-15 | Secora Michael Chief Financial Officer | Shares withheld for taxes | −7,172 | $12.43 | $89K | 1,179,179 |
| 2024-02-15 | Marriott Tina President and COO | Shares withheld for taxes | −5,379 | $12.43 | $67K | 639,982 |
| 2024-02-15 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes | −11,148 | $12.43 | $139K | 1,104,919 |
| 2024-02-14 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 1,211,351 |
| 2024-02-14 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −23,933 | $10.43 | $250K | 1,187,418 |
| 2024-02-14 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −1,067 | $10.98 | $12K | 1,186,351 |
| 2024-02-14 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 960,135 | ||
| 2024-02-13 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 1,198,851 |
| 2024-02-13 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $9.86 | $247K | 1,173,851 |
| 2024-02-13 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 997,635 | ||
| 2024-02-09 | Mauro David J Chief Medical Officer | Grant or award | +6,040 | 196,753 | ||
| 2024-02-09 | Mauro David J Chief Medical Officer | Grant or award | +49,768 | 246,521 | ||
| 2024-02-09 | Mauro David J Chief Medical Officer | Shares withheld for taxes | −1,892 | $10.09 | $19K | 244,629 |
| 2024-02-09 | Mauro David J Chief Medical Officer | Grant or award · Stock Option (RIght to Buy) | +99,537 | 99,537 | ||
| 2024-02-09 | Secora Michael Chief Financial Officer | Grant or award | +8,659 | 989,673 | ||
| 2024-02-09 | Secora Michael Chief Financial Officer | Grant or award | +174,190 | 1,163,863 | ||
| 2024-02-09 | Secora Michael Chief Financial Officer | Shares withheld for taxes | −2,512 | $10.09 | $25K | 1,161,351 |
| 2024-02-09 | Secora Michael Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +348,380 | 348,380 | ||
| 2024-02-09 | Marriott Tina President and COO | Grant or award | +9,655 | 424,203 | ||
| 2024-02-09 | Marriott Tina President and COO | Grant or award | +223,958 | 648,161 |
Page 24 of 41 · 805 trades